Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. (Q53059036)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published in May 2014

Language	Label	Description	Also known as
English	Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.	scientific article published in May 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

0 references

0 references

cannabinoid receptor

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

José L. Lanciego

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Christa E Müller

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

12

object named as

Marie Therese Armentero

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

2

object named as

Giovanna Levandis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Giulia Ambrosi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Elena Montepeloso

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Gian Filippo Antoninetti

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

1 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Journal of Neuropathology & Experimental Neurology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

73

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

414-424

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24709676%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Levodopa motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Treatment strategies for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Therapies in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Association of coffee and caffeine intake with the risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Targeting adenosine A2A receptors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine receptor signaling in the brain immune system

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Cannabinoids and neuroprotection in basal ganglia disorders.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Cannabinoids and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Unbiased stereological estimation of the number of neurons in the human hippocampus

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Endocannabinoids mediate neuron-astrocyte communication

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Astrocytes and Therapeutics for Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

The 6-hydroxydopamine model: news from the past

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A(2A) receptor mediates microglial process retraction

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Microglial cell activation and proliferation precedes the onset of CNS autoimmunity

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Comparison of polarization properties of human adult microglia and blood-derived macrophages

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000064

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53059036&oldid=2269936429"